External Innovation

Global Oncology External Innovation Hub

As our priority area of research, Boston Biomedical is committed to propelling drug discovery in oncology. To help spark meaningful research in this space, our parent organization, Sumitomo Dainippon Pharma, made a significant investment to establish a Global Oncology External Innovation Hub in Cambridge, Mass., to enhance collaboration with those that share in our joint pursuit to fight cancer with science.

Through the External Innovation efforts led by Sumitomo Dainippon Pharma, we are expanding our research partnerships to advance the discovery of novel therapeutics.

Strategic Alliances

In December 2019, we entered into an alliance with three world-leading oncology centers of excellence—Columbia University, Harvard University and The Wistar Institute. Through this alliance we are supporting research endeavors dedicated to finding novel targets and platform technologies for the development of cancer drugs.

By leveraging each institution’s unique technologies and therapeutic insights to pursue specific research areas, we believe this agreement will bring us closer to filling unmet needs in oncology. More details on the alliance can be found in our press release.

“Innovation is at the core of everything that Sumitomo Dainippon Pharma does, and the establishment of the Global Oncology External Innovation Hub exemplifies our commitment to oncology and drug discovery. It is our vision that our external innovation efforts will help us grow our understanding of cancer as a disease and, most importantly, lead to identifying new treatments for patients with cancer.”

- Dr. Mahmoud Mahmoudian,
Senior Vice President, Head of Global Oncology External Innovation,
Sumitomo Dainippon Pharma Global Oncology